Two or three issues side by side. Only issues that are open, upcoming or awaiting listing appear — those are the ones a comparison can act on, and the ones whose figures are actually published.
3 is the most that fits side by side. Remove one to add another.
| Comparing | AP Annu ProjectsMainboard · Upcoming | SP Symbiotec Pharmalab LimitedMainboard · Upcoming | AE Augmont Enterprises LimitedMainboard · Upcoming |
|---|---|---|---|
| Issue | |||
| Board | Mainboard | Mainboard | Mainboard |
| Status | Upcoming | Upcoming | Upcoming |
| Price band | — | ₹938 – ₹988 | ₹750 – ₹788 |
| Lot size | — | 15 shares | |
A row is shown only where at least one of these issues has published the figure; a dash means that company has not. Nothing here is a recommendation — CAPITA1 is not registered with SEBI as an investment adviser or a research analyst.
| 19 shares |
| Minimum investmentOne lot at the upper band | — | ₹14,820 | ₹14,972 |
|---|
| Issue size | — | ₹1,757 Cr | ₹825 Cr |
|---|
| Face value | — | ₹2 | ₹5 |
|---|
| Registrar | — | MUFG Intime India Private Limited | MUFG Intime India Private Limited |
|---|
| Timeline | |||
|---|---|---|---|
| Open date | 25 Aug 2026 | 24 Aug 2026 | 21 Aug 2026 |
| Close date | 28 Aug 2026 | 27 Aug 2026 | 25 Aug 2026 |
| Allotment date | 31 Aug 2026 | 28 Aug 2026 | 26 Aug 2026 |
| Listing date | 2 Sep 2026 | 1 Sep 2026 | 28 Aug 2026 |
| Valuation | |||
|---|---|---|---|
| P/E ratioAt the upper band. Null where earnings are negative. | — | 51.73x | 19.48x |
| EPS | ₹6.91 | ₹19.1 | ₹40.45 |
| NAV per share | ₹32.48 | ₹184.69 | ₹111 |
| Return on equity | 21.27% | 11.19% | 51.04% |
| Return on net worth | 21.27% | 9.48% | 49.52% |
| Return on capital employed | 22.66% | 11.56% | 40.27% |
| EBITDA margin | 20.81% | 26.59% | 0.41% |
| Debt to equity | — | — | 0.01 |
| Market | |||
|---|---|---|---|
| Grey market premiumUnofficial estimate — not an exchange price | — | — | ₹160 |
| Subscribed (overall) | — | 0.00x | 0.00x |